Surgery, Gastroenterology and Oncology
Vol. 24, No. 1, Feb 2019
miRNA 200 Family Expression is a Strong Predictor for Recurrence Following Liver Resection for Breast Cancer Liver Metastases
Nicolae Bacalbaşa, Irina Bălescu, Veronica Ilie, Raluca Florea, Andrei Sorop, Vladislav Braşoveanu, Mihaela Vilcu, Iulian Brezean, Simona Dima, Irinel Popescu
ORIGINAL PAPER, Feb 2019
Article DOI: 10.21614/sgo-24-1-15
Although only a small percent of breast cancer patients are diagnosed in metastatic stages, a significantly higher percent will develop disseminated recurrences at a certain point of their evolution, this event being responsible for a high number of cancer relate deaths.
In recent years a particular attention was paid for identifying the factors which might be responsible for the development of metastatic disease.
The current study included 27 patients submitted to surgery for breast cancer liver metastases in Dan Setlacec Center of Gastrointestinal Diseases and Liver Transplantation Fundeni Clinical Institute, Bucharest Romania.
In all cases miRNA expression was studied in both tumoral and non-tumoral tissues. miRNA species which were proved to be supra-expressed in the tumoral areas included mainly the miRNA 200 family (miR-200c and miR-141).
These results demonstrate that alterations in miRNA-200 family play a key role in development of breast cancer liver metastatic process. In the meantime miRNA family seems to be a strong predictor for recurrence following liver resection for breast cancer liver metastases.
Therefore, these molecules might become an useful signature in identifying high risk breast cancer patients; moreover this analysis seem to provide a better selection of patients who could benefit most from hepatic resection for breast cancer liver metastases. In this way, a significant improvement of overall survival after liver resection is expected. In the meantime, miRNA analysis could also indicate which patients are less probably to benefit from surgery and could straighten them to other personalized therapeutic strategies.

Full Text Sources: Download pdf
Abstract:   Abstract EN
Views: 3042


Watch Video Articles


For Authors



Journal Subscriptions

Current Issue

Dec 2025

Supplements

Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)

e-ISSN: 2601 - 1700 (online)

ISSN-L: 2559 - 723X

Journal Abbreviation: Surg. Gastroenterol. Oncol.

Surgery, Gastroenterology and Oncology (SGO) is indexed in:
  • SCOPUS
  • EBSCO
  • DOI/Crossref
  • Google Scholar
  • SCImago
  • Harvard Library
  • Open Academic Journals Index (OAJI)

Open Access Statement

Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.

Journal Metrics

Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2



Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019

Creative Commons License
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/
Publisher’s Note:
The opinions, statements, and data contained in article are solely those of the authors and not of Surgery, Gastroenterology and Oncology journal or the editors. Publisher and the editors disclaim responsibility for any damage resulting from any ideas, instructions, methods, or products referred to in the content.